Biodistribution and dosimetry results form a phase III prospectively randomized controlled trial of zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Wiseman GA, White CA, Sparks RB, Erwin WD, Pololoff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR. Biodistribution and dosimetry results form a phase III prospectively randomized controlled trial of zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology Hematology. 2001; 39:181-194..